PSTX News and Press, Poseida Therapeutics Inc. From 12/13/21

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting P-BCMA-101 demonstrated strong anti-tumor activity and was well tolerated in nearly 100 patients with R/R multiple myeloma at the time of d...

The following slide deck was published by Poseida Therapeutics, Inc. in conjunction with this event. For further details see: Poseida Therapeutics (PSTX) Presents At Stifel 2021 Virtual Healthcare Conference - Slideshow

Poseida Therapeutics (NASDAQ:PSTX): Q3 GAAP EPS of -$0.68 beats by $0.07. Cash, cash equivalents and short-term investments of $197.81M. Press Release For further details see: Poseida Therapeutics EPS beats by $0.07

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 Clearance of IND by FDA and clinical trial start-up for P-BCMA-ALLO1 begins planned strategic shift to allogeneic BCMA CAR-T program for patients with multiple myeloma; P-BCMA-101 a...

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting Poseida's piggyBac® DNA delivery system, Cas-CLOVER™ site-specific gene editing system, and Poseida'...

Poseida has built a non-viral genome engineering platform to develop safer cell therapies in oncology. This platform could enable outpatient use and expand the number of patients who can receive a cell therapy as well as bringing in substantial partnerships. Poseida's lead drug ca...

Poseida Therapeutics Announces Leadership Appointments PR Newswire SAN DIEGO , Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to c...

R. R. Donnelley & Sons (NYSE:RRD) +31%. Inhibrx (NASDAQ:INBX) +17% on favorable safety profile in patients with alpha-1 antitrypsin deficiency and demonstrates the potential to achieve normal alpha-1 antitrypsin levels with monthly dosing. Protara Therapeutics (NASDAQ:TARA) +26%...

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies Collaboration to leverage Poseida's non-viral piggyBac® DNA Modification System, Cas-CLOVER™ Site-Specific Gene Editing System, biodegradable DNA and RNA nano...

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting PR Newswire SAN DIEGO , Oct. 1, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic eng...